What should be done if a patient deteriorates while receiving Zavicefta (ceftazidime‑avibactam) and aztreonam combination?

Management of Clinical Deterioration on Zavicefta-Aztreonam Combination

If a patient deteriorates on ceftazidime-avibactam plus aztreonam combination therapy, immediately add polymyxin or fosfomycin to the regimen while urgently repeating cultures and susceptibility testing to identify resistance emergence or alternative pathogens.

Immediate Actions

When clinical deterioration occurs despite combination therapy:

1. Augment Current Therapy

• Add polymyxin B or colistin to the existing ceftazidime-avibactam plus aztreonam regimen 1
• Consider adding fosfomycin as an alternative or additional agent 1
• The 2023 guidelines explicitly mention that polymyxin or fosfomycin were added "if indicated" in cases where the dual combination alone was insufficient 1

2. Investigate Resistance Development

• Repeat blood cultures and susceptibility testing immediately - resistance to ceftazidime-avibactam can develop in 3.8-10.4% of patients during treatment 2
• Reconfirm carbapenemase type - initial testing may miss co-production of multiple carbapenemases (e.g., both KPC and NDM) 3
• Request synergy testing if not previously performed - the combination is not universally synergistic 4

3. Consider Alternative Diagnoses

• Evaluate for superinfection with different organisms (e.g., CRAB, other resistant pathogens) 5
• Assess for non-infectious causes of deterioration
• Review source control adequacy - undrained abscesses or inadequate surgical debridement

Evidence-Based Rationale

The 2023 guidelines show that even with ceftazidime-avibactam plus aztreonam, the overall mortality rate was 21% in metallo-β-lactamase-producing CRE infections 1. The studies specifically noted that some patients received "plus polymyxin or fosfomycin if indicated," suggesting these agents serve as rescue therapy 1.

Critical caveat: The combination shows synergy in only 62.5% of cases in recent data 6, and synergy-positive cases had better outcomes (31.3% clinical improvement) versus synergy-negative cases (12.5% improvement) 6. This explains why some patients fail despite appropriate therapy.

Specific Augmentation Strategy

For Metallo-β-lactamase Producers (NDM, VIM, IMP):

• First-line augmentation: Add polymyxin B or colistin 1, 2
• Alternative: Add fosfomycin (particularly for urinary tract infections) 1
• Consider triple therapy: Ceftazidime-avibactam + aztreonam + aminoglycoside (amikacin or plazomicin) - emerging data shows this reduces bacterial turbidity and filamentous cell formation 7

Dosing Considerations:

• Ensure prolonged infusion (3-hour) of ceftazidime-avibactam - associated with improved 30-day survival 2
• Verify appropriate renal dose adjustments 2
• Use high-dose aztreonam if not already prescribed

When to Switch Completely

If deterioration continues despite augmentation:

1. For CNS infections: Consider topical polymyxin B irrigation via drainage catheter in addition to systemic therapy 3
2. If new resistance confirmed: Switch to cefiderocol if available and organism susceptible 2
3. For polymyxin-only susceptible isolates: The 2022 ESCMID guidelines suggest combination therapy with two active agents when only older antibiotics remain 2

Monitoring Parameters

• Daily SOFA score - failure to improve by day 4 predicts poor outcome 8
• Repeat cultures at 48-72 hours to document microbiological clearance
• Renal function closely if adding polymyxins 1
• Lactate levels and PaO2/FiO2 ratio - independent predictors of mortality 8

Common Pitfall

Do not assume the combination is working simply because it was prescribed - the evidence shows variable synergy and the guidelines acknowledge "very low quality evidence" for this regimen 1. Early recognition of failure and aggressive augmentation is critical given the 21% baseline mortality rate even with optimal therapy 1.